Genmab — Oktober 2019
-
og falder lidt igen
-
331 besøgende nu.
-
skulle man lave en blindebuk investering
-
Bull - eller chicken
-
23 fra Holland. De har storskærm i kantinen hos Genmab.
-
Vise ord, Legolas
-
765
-
GENMAB: DARZALEX-FSG 765 MLN USD 3 KV ENL J&J
12:46
STOCKHOLM (Nyhetsbyrån Direkt) Den globala försäljningen av Darzalex (daratumumab) uppgick till 765 miljoner dollar under det tredje kvartalet 2019 (498), jämfört med väntade 594 miljoner dollar enligt snittet av två analytikerestimat enligt Bloomberg.Det framgår av Johnson & Johnsons rapport.
Genmab får royalties på den globala nettoförsäljningen av Darzalex enligt licensavtalet med Janssen Biotech.
Kristine Trapp +46 8 5191 7927
Magn -
Johnson & Johnson Reports 2019 Third-Quarter Results
/PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced results for third-quarter 2019. "Our third-quarter results represent strong performance, driven...
(www.prnewswire.com)
-
Net
sales were USD 402 million in the U.S. and USD 363 million in the rest of
the world. Genmab will receive royalties on the worldwide net sales of
DARZALEX under the exclusive worldwide license to Janssen Biotech, Inc. to
develop, manufacture and commercialize DARZALEX. -
en hurtig udregning ifht mine estimater (uden maia) siger at maia giver et bump på ca usd +20m
-
dvs recepttallene for sept ligger I usd 160-165m området. Det er rigtig godt
-
som forventet, vi når ihvertfald i mål med de 3 mill dollars
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind